MYSOLINE Drug Patent Profile
When do Mysoline patents expire, and when can generic versions of Mysoline launch?
Mysoline is a drug marketed by Valeant and is included in one NDA.
The generic ingredient in MYSOLINE is primidone. There is one drug master file entry for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the primidone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mysoline
A generic version of MYSOLINE was approved as primidone by WATSON LABS on December 31st, 1969.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MYSOLINE?
- What are the global sales for MYSOLINE?
- What is Average Wholesale Price for MYSOLINE?
Summary for MYSOLINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 86 |
| Clinical Trials: | 5 |
| Patent Applications: | 4,517 |
| Drug Prices: | Drug price information for MYSOLINE |
| What excipients (inactive ingredients) are in MYSOLINE? | MYSOLINE excipients list |
| DailyMed Link: | MYSOLINE at DailyMed |
Recent Clinical Trials for MYSOLINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Dr. Reddy's Laboratories Limited | Phase 1 |
| Mutual Pharmaceutical Company, Inc. | Phase 1 |
Pharmacology for MYSOLINE
| Drug Class | Anti-epileptic Agent |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
US Patents and Regulatory Information for MYSOLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant | MYSOLINE | primidone | TABLET;ORAL | 009170-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Valeant | MYSOLINE | primidone | TABLET;ORAL | 009170-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
MYSOLINE (PRIMIDONE) MARKET DYNAMICS, PATENT STATUS, AND FINANCIAL TRAJECTORY
Mysoline is the brand name for primidone, an oral antiseizure medicine also used for essential tremor. Its commercial profile is that of a mature, low-cost generic market rather than an actively protected branded product. The original product has no meaningful remaining composition-of-matter exclusivity, generic primidone is widely available, and public company filings generally do not disclose Mysoline revenue separately. Financial performance therefore depends on generic prescription volume, supply continuity, manufacturing costs, reimbursement, and channel pricing rather than brand-driven price power.
What is Mysoline, and what therapeutic markets does it serve?
Mysoline contains primidone, a barbiturate-related anticonvulsant. The FDA-approved labeling identifies its use in grand mal, psychomotor, and focal epileptic seizures. Primidone is also prescribed for essential tremor, although that use is generally treated as an off-label indication in the United States (U.S. Food and Drug Administration [FDA], n.d.; National Library of Medicine, n.d.).
| Attribute | Mysoline / primidone |
|---|---|
| Active ingredient | Primidone |
| Primary therapeutic area | Epilepsy |
| Important secondary use | Essential tremor |
| Dosage forms | Oral tablets; oral suspension or compounded liquid may be used in some markets |
| Common tablet strengths | 50 mg, 125 mg, and 250 mg, depending on manufacturer |
| U.S. regulatory status | Approved prescription drug; multiple generic products |
| Reference product | Mysoline |
| Commercial maturity | Long-established, off-patent product |
| Main competitors | Generic primidone tablets from multiple manufacturers |
| Key substitutes | Phenobarbital, levetiracetam, valproate, carbamazepine, phenytoin, topiramate, propranolol for essential tremor |
Primidone is metabolized partly to phenobarbital and phenylethylmalonamide. Its use requires attention to sedation, ataxia, cognitive effects, drug interactions, and gradual dose adjustment. Those clinical characteristics limit its role in some newly diagnosed patients but support continued use in selected epilepsy and tremor populations.
When did Mysoline lose exclusivity?
Mysoline lost practical market exclusivity many years ago. Primidone was introduced in the 1950s, and the product’s original patent and regulatory exclusivity periods expired decades ago. The current commercial market is therefore governed by generic competition rather than by a protected brand franchise.
The important distinction is between:
- Patent expiration for the original active ingredient.
- FDA approval of generic primidone products.
- Any later patents covering a specific formulation, manufacturing process, or delivery technology.
For standard immediate-release primidone tablets, there is no evident current patent barrier comparable to the barriers protecting newer small-molecule products. Generic manufacturers can compete through abbreviated new drug applications, subject to FDA requirements for pharmaceutical equivalence, manufacturing quality, and bioequivalence.
Mysoline exclusivity timeline
| Period | Commercial event | Market effect |
|---|---|---|
| 1950s | Primidone introduced as Mysoline | Brand-led market formation |
| Following decades | Original patent and regulatory protections expire | Generic entry becomes legally possible |
| Late 20th century onward | Generic primidone products enter the market | Price competition increases |
| Current market | Generic primidone is broadly available | Brand pricing power is limited |
What is the Orange Book status of Mysoline?
The FDA Orange Book is the principal U.S. source for approved drug products, therapeutic-equivalence evaluations, and certain patent and exclusivity information. Mysoline is associated with an old reference-product approval, while generic primidone products are listed as therapeutically equivalent where the relevant FDA standards are met (FDA, n.d.-a).
The commercial significance of the Orange Book position is limited:
- Standard primidone tablets are exposed to generic substitution.
- No current brand exclusivity appears to support premium pricing.
- Any active listing would need to be evaluated at the product and dosage-form level.
- Generic entrants generally do not need to overcome a modern compound patent for primidone.
An Orange Book listing does not itself indicate that the branded product generates substantial revenue. It primarily establishes the regulatory reference framework for generic approval and substitution.
How many patents protect Mysoline?
No commercially important active patent estate is apparent for the original primidone molecule or standard Mysoline immediate-release tablets. The relevant protection is historical, not strategic.
| Patent category | Current commercial relevance |
|---|---|
| Primidone composition-of-matter patents | Expired |
| Standard tablet formulation patents | No meaningful barrier identified |
| Method-of-use patents for epilepsy | No current barrier comparable to newer therapies |
| Essential-tremor use claims | Primidone’s use is generally supported by clinical practice and literature rather than a high-value exclusivity position |
| Manufacturing patents | Potentially relevant to individual suppliers, but not a broad barrier to generic supply |
| Drug-device patents | Not central to the standard Mysoline product |
A company could seek patent protection for a new sustained-release formulation, combination product, liquid formulation, or delivery system. That would protect the specific improvement, not the underlying primidone molecule. No such improvement appears to define the current Mysoline market.
Are there Paragraph IV challenges involving Mysoline?
Paragraph IV litigation is unlikely to be a material issue for standard primidone. Paragraph IV certifications are most commercially important when an ANDA applicant challenges an unexpired Orange Book-listed patent. Because the core primidone product is long off patent, generic approval does not depend on defeating a valuable modern patent estate.
The expected legal pattern is:
- Generic entry through ANDAs.
- No major patent trial centered on the primidone molecule.
- Limited commercial value in defending the old brand.
- Potential disputes focused on manufacturing, labeling, supply, trademarks, or specific reformulations rather than core composition patents.
No major current Mysoline-specific Paragraph IV litigation is widely reported in the public record reviewed for this analysis.
What formulations are protected by Mysoline patents?
The commercially established Mysoline formulation is an immediate-release oral tablet. Its value comes from the active ingredient and established prescribing base, not from a differentiated delivery system.
Potential formulation opportunities include:
- Extended-release primidone.
- Lower-dose titration tablets.
- Oral liquid products for patients with swallowing difficulties.
- Combination products involving primidone and another anticonvulsant.
- Modified formulations designed to reduce sedation or smooth metabolite exposure.
These opportunities face technical and commercial constraints. Primidone is an old molecule with established generic alternatives. A new formulation would need to show a meaningful clinical, pharmacokinetic, adherence, or safety advantage. FDA approval alone would not guarantee reimbursement or prescriber switching.
What is the FDA regulatory status of Mysoline?
Mysoline is an FDA-approved prescription product. Generic primidone products are approved under the ANDA pathway when they demonstrate pharmaceutical equivalence and bioequivalence to the reference product or satisfy applicable FDA requirements (FDA, n.d.-b).
The regulatory environment is relatively predictable:
- The product is a small-molecule oral solid.
- No biologic comparability or biosimilar pathway applies.
- Manufacturing is subject to current good manufacturing practice requirements.
- Labeling changes may arise from safety updates, supply changes, or manufacturer-specific product status.
- Generic substitution is governed by state pharmacy law and payer policy.
Is there biosimilar risk for Mysoline?
No. Biosimilars apply to biological products, not to primidone. Mysoline faces generic substitution risk, not biosimilar competition. This distinction matters because generic entry is usually less expensive and procedurally simpler than biosimilar development.
Which companies compete with Mysoline?
The competitive field consists primarily of generic drug manufacturers and distributors. Product availability can change as companies enter, discontinue, or consolidate their portfolios.
The relevant competitive groups include:
- Established generic manufacturers with ANDA portfolios.
- Specialty and hospital suppliers.
- Contract manufacturers.
- Pharmacy wholesalers and purchasing organizations.
- Compounding pharmacies supplying liquid or customized doses.
Brand competition is weak. The central competitive variables are:
| Variable | Effect on market |
|---|---|
| Wholesale acquisition price | Determines payer and pharmacy economics |
| Contract reliability | Important because epilepsy patients may be sensitive to supply interruptions |
| Tablet strength availability | Affects titration and prescribing convenience |
| FDA manufacturing history | Can cause shortages or supplier exits |
| Wholesaler coverage | Determines pharmacy access |
| Therapeutic substitution | Limits demand growth for primidone |
| Patient continuity | Supports recurring prescriptions in established users |
What is the financial trajectory of Mysoline?
Publicly available financial data do not support a separate Mysoline revenue series. Manufacturers typically report generic portfolios in aggregate, without isolating revenue for an old product such as primidone. The financial trajectory is therefore best assessed through market structure.
Historical trajectory
Mysoline likely generated its strongest commercial economics during the branded period, when the originator controlled pricing, promotion, and distribution. After generic entry, unit volume could remain stable or decline gradually while revenue and gross margin fell sharply.
Current trajectory
The product is a low-growth, price-sensitive generic. Revenue is shaped by:
- Stable chronic use in epilepsy and essential tremor.
- Declining average selling prices.
- Generic substitution.
- Periodic supply shortages.
- Reduced physician promotion.
- Limited patient switching because some long-term users remain clinically stable on a familiar product.
- Competition from newer anticonvulsants.
A simplified lifecycle model is:
| Lifecycle stage | Revenue pattern | Margin profile |
|---|---|---|
| Branded launch | Rising demand | High branded margin |
| Mature branded period | Stable or growing revenue | Strong margin if protected |
| Generic entry | Rapid price erosion | Margin compression |
| Mature generic period | Stable unit demand, low revenue growth | Low-to-moderate margin |
| Supply-constrained period | Temporary price and volume volatility | Margin can improve for remaining suppliers |
There is no public basis for assigning a precise annual Mysoline revenue figure. Any estimate presented as a standalone brand number would risk conflating Mysoline with total primidone sales or with the broader epilepsy market.
What generic entry risks exist for Mysoline?
Generic entry risk is already realized rather than prospective. The principal commercial risks now relate to erosion and substitution.
Revenue risks
- Pharmacy substitution away from the brand.
- Payer preference for the lowest-cost generic.
- Loss of formulary position.
- Declining brand recognition among younger prescribers.
- Manufacturer discontinuations that reduce market continuity.
Operational risks
- Shortages of specific strengths.
- Dependence on a small number of active pharmaceutical ingredient suppliers.
- FDA inspections or warning letters affecting manufacturers.
- Wholesaler inventory compression.
- Product recalls.
Clinical and switching risks
Epilepsy patients can be sensitive to changes in dose, formulation, adherence, and serum exposure. Even where products are therapeutically equivalent, prescribers may prefer continuity for patients who are stable on a particular manufacturer’s product. That factor can support a narrow premium for reliable supply, but it does not recreate branded exclusivity.
What patent litigation affects Mysoline?
No major current patent litigation appears to define the Mysoline market. The absence of litigation is itself commercially relevant: the principal barriers are no longer legal exclusivity but low economics, manufacturing execution, and clinical substitution.
Potential disputes could involve:
- Trademark use of the Mysoline name.
- Product liability.
- Manufacturing defects.
- Labeling and safety claims.
- Distribution agreements.
- Reformulated or extended-release products.
Those matters would not create a broad monopoly over ordinary primidone tablets.
How does Mysoline compare with newer epilepsy drugs?
Mysoline has a lower acquisition cost but a less favorable modern tolerability and convenience profile for many patients. Newer medicines often command greater commercial value because of differentiated safety, dosing, interaction, or adherence attributes.
| Factor | Mysoline / primidone | Newer anticonvulsants |
|---|---|---|
| Patent position | Generally expired | May retain patents or exclusivity |
| Price | Low generic price | Often higher, especially before generic entry |
| Sedation risk | Clinically important | Varies by product |
| Drug interactions | Relevant through metabolism | Product-specific |
| Physician promotion | Minimal | Often active during exclusivity |
| Revenue potential | Low | Higher for protected products |
| Essential tremor role | Established off-label use | Limited alternatives, including propranolol |
| Switching sensitivity | Important in stable patients | Depends on product and indication |
How strong is the Mysoline patent estate?
The Mysoline patent estate is weak as a current commercial asset. Its strength is effectively zero for the underlying molecule and low for standard tablets. The product’s remaining value is based on:
- Existing clinical familiarity.
- Chronic-use patient retention.
- Regulatory approval history.
- Manufacturing know-how.
- Distribution relationships.
- Supply reliability.
Those assets can support a profitable generic product at sufficient volume, but they do not support premium valuation based on exclusivity.
What licensing deals involve Mysoline?
No major recent licensing transaction appears to have repositioned Mysoline as a growth asset. Licensing economics for an old generic product would more likely involve:
- Regional distribution rights.
- Transfer of a marketed product portfolio.
- Contract manufacturing.
- Acquisition of an ANDA.
- Rights to a reformulated or combination product.
A transaction involving Mysoline alone would likely have limited strategic value unless it included manufacturing capacity, a broader neurology portfolio, or a differentiated formulation.
What geographic markets matter for Mysoline?
The commercial profile varies by jurisdiction.
United States
The United States is a generic, substitution-driven market. FDA approval, state substitution rules, payer formularies, and wholesaler supply determine commercial performance.
Europe
Primidone access is shaped by national reimbursement systems, reference pricing, tendering, and country-specific marketing authorizations. Brand retention is generally weak where generic substitution and centralized price controls are strong.
Emerging markets
Demand may persist where epilepsy treatment access is expanding and low-cost oral anticonvulsants remain important. Regulatory registration, local manufacturing, import controls, and distribution reach are more important than patent protection.
What manufacturing and intellectual-property barriers remain?
The principal remaining barriers are practical rather than patent-based:
- Reliable production of pharmaceutical-grade primidone.
- Consistent tablet dissolution and content uniformity.
- Control of impurities and degradation products.
- Compliance with FDA and international GMP standards.
- Stable supply of active pharmaceutical ingredient.
- Maintenance of multiple approved strengths.
- Quality systems for chronic-use medicines.
A manufacturer with reliable supply can gain share during competitor shortages. That advantage is usually temporary and operational. It does not create durable exclusivity unless supported by a protected formulation or a proprietary manufacturing process.
Key Takeaways
- Mysoline is the long-established brand for primidone, an oral anticonvulsant also used for essential tremor.
- The original molecule and standard tablet formulation are long off patent.
- Generic primidone is the dominant commercial model.
- No current Mysoline-specific patent estate appears capable of blocking ordinary generic entry.
- Paragraph IV litigation is not a central market issue.
- FDA approval and Orange Book status support generic substitution rather than branded pricing power.
- There is no biosimilar risk because primidone is a small molecule.
- Public companies generally do not disclose Mysoline revenue separately.
- The financial trajectory is one of post-exclusivity erosion, low pricing, stable chronic demand, and supply-driven volatility.
- Future value would require a differentiated formulation, combination product, or broader neurology portfolio.
FAQs
Is Mysoline still sold in the United States?
Mysoline has historically been marketed in the United States, while generic primidone is widely available. Product availability and manufacturer status can vary by strength and supplier.
Is primidone a controlled substance?
Primidone itself is not generally treated as a federally controlled substance in the same manner as phenobarbital, although it is metabolized partly to phenobarbital and remains subject to prescription controls and clinical monitoring.
Can pharmacies automatically substitute generic primidone for Mysoline?
Substitution depends on FDA therapeutic-equivalence status, state law, payer rules, and any prescriber instruction limiting substitution. Pharmacies commonly dispense generic primidone when permitted.
Does primidone have a patent for essential tremor?
The underlying primidone molecule is long off patent. Use of primidone for essential tremor is generally supported by clinical evidence and medical practice rather than a commercially significant active-use patent estate.
Could a new extended-release primidone product obtain market exclusivity?
Yes. A qualifying new formulation could obtain patents and regulatory exclusivity for the improved product. That protection would cover the new formulation or approved use, not ordinary immediate-release primidone tablets.
References
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.-b). Abbreviated new drug application (ANDA). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
U.S. Food and Drug Administration. (n.d.). Mysoline (primidone) prescribing information. Drugs@FDA.
-
National Library of Medicine. (n.d.). Primidone: MedlinePlus drug information. https://medlineplus.gov/druginfo/meds/a682023.html
More… ↓



